Skip to main content

Advertisement

SpringerLink
Log in

Non-Hodgkin’s lymphoma in children and adolescents

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Lymphoma is the third most common cancer in children and adolescents. Non-Hodgkin’s lymphomas comprise a heterogeneous group of tumors with distinct pathologic and clinical characteristics. Over the past three decades, significant advancements have been made in the molecular characterization of these disorders. With the use of intensive multiagent chemotherapy, non-Hodgkin’s lymphomas are now among the most successfully treated cancers in the pediatric population. Future goals of therapy include reduction of treatment duration for early-stage patients and identification of novel targets and therapeutics for advanced-stage patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ries LAG, Smith MA, Gurney JG, et al. (eds): Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD; 1999.

  2. Magrath IT: Malignant non-Hodgkin’s lymphomas in children. In Principles and Practice of Pediatric Oncology. Edited by Pizzo PA, Poplack DG. Philadelphia: Lippincott Williams & Wilkins; 2002:661–705.

    Google Scholar 

  3. Murphy SB, Fairclough DL, Hutchison RE, Berard CW: Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989, 7:186–193.

    PubMed  CAS  Google Scholar 

  4. Biggar RJ, Frisch M, Goedert JJ: Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group. JAMA 2000, 284:205–209.

    Article  PubMed  CAS  Google Scholar 

  5. Granovsky MO, Mueller BU, Nicholson HS, et al.: Cancer in human immunodeficiency virus-infected children: a case series from the Children’s Cancer Group and the National Cancer Institute. J Clin Oncol 1998, 16:1729–1735.

    PubMed  CAS  Google Scholar 

  6. Gaidano G, Carbone A, Dalla-Favera R: Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J Natl Cancer Inst Monogr 1998, 23:95–100.

    PubMed  Google Scholar 

  7. Taylor AM, Metcalfe JA, Thick J, Mak YF: Leukemia and lymphoma in ataxia telangiectasia. Blood 1996, 15:423–438.

    Google Scholar 

  8. Gumy-Pause F, Wacker P, Sappino AP: ATM gene and lymphoid malignancies. Leukemia 2004, 18:238–242.

    Article  PubMed  CAS  Google Scholar 

  9. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA: A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994, 125:876–885.

    Article  PubMed  CAS  Google Scholar 

  10. Sandlund JT, Downing JR, Crist WM: Non-Hodgkin’s lymphoma in childhood. N Engl J Med 1996, 334:1238–1248.

    Article  PubMed  CAS  Google Scholar 

  11. Sasaki M, Kuwabara Y, Koga H, et al.: Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002, 16:337–345.

    Article  PubMed  Google Scholar 

  12. Montravers F, McNamara D, Landman-Parker J, et al.: [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002, 29:1155–1165.

    Article  PubMed  CAS  Google Scholar 

  13. Jerusalem G, Beguin Y, Fassotte MF, et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999, 94:429–333.

    PubMed  CAS  Google Scholar 

  14. Spaepen K, Stroobants S, Dupont P, et al.: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001, 19:414–419.

    PubMed  CAS  Google Scholar 

  15. Depas G, De Barsy C, Jerusalem G, et al.: 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005, 32:31–38.

    Article  PubMed  Google Scholar 

  16. Allen-Auerbach M, Quon A, et al.: Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004, 6:411–416.

    Article  PubMed  Google Scholar 

  17. Lones MA, Perkins SL, Sposto R, et al.: Non-Hodgkin’s lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children’s Cancer Group report. J Clin Oncol 2002, 20:2293–2301.

    Article  PubMed  Google Scholar 

  18. Seidemann K, Zimmermann M, Book M, et al.: Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin’s lymphoma: results from Berlin-Frankfurt-Munster Trial NHL-BFM 95. J Clin Oncol 2005, 23:8414–8421.

    Article  PubMed  CAS  Google Scholar 

  19. LaQuaglia MP, Stolar CJ, Krailo M, et al.: The role of surgery in abdominal non-Hodgkin’s lymphoma: experience from the Childrens Cancer Study Group. J Pediatr Surg 1992, 27:230–235.

    Article  PubMed  CAS  Google Scholar 

  20. Cairo MS, Gerrard M, Sposto R, et al.: Results of a randomized FAB LMB96 international study in children and adolescents (C+A) with advanced B-NHL: Pts with L3 leukemia/CNS-have an excellent prognosis [abstract]. Proc ASCO 2003, 22:3199.

    Google Scholar 

  21. Wollner N, Burchenal JH, Lieberman PH, et al.: Non-Hodgkin’s lymphoma in children. Med Pediatr Oncol 1975, 1:235–263.

    Article  PubMed  CAS  Google Scholar 

  22. Cairo MS, Sposto R, Perkins SL, et al.: Burkitt’s and Burkitt-like lymphoma in children and adolescents: a review of the Children’s Cancer Group experience. Br J Haematol 2003, 120:660–750.

    Article  PubMed  Google Scholar 

  23. Patte C, Auperin A, Michon J, et al.: The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370–3379. This study by the SFOP demonstrated effective therapy against all stages of Burkitt’s and large B-cell lymphomas using a stratified treatment approach.

    Article  PubMed  CAS  Google Scholar 

  24. Patte C, Kalifa C, Flamant F, et al.: Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 1992, 20:105–113.

    Article  PubMed  CAS  Google Scholar 

  25. Meadows AT, Sposto R, Jenkin RD, et al.: Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin’s lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 1989, 7:92–99.

    PubMed  CAS  Google Scholar 

  26. Mora J, Filippa DA, Qin J, Wollner N: Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 2003, 98:1283–1291.

    Article  PubMed  Google Scholar 

  27. Reiter A, Schrappe M, Ludwig WD, et al.: Intensive ALLtype therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000, 95:416–421. This study by the BFM group demonstrated the benefit of intensive ALL-type therapy for lymphoblastic lymphoma patients.

    PubMed  CAS  Google Scholar 

  28. Neth O, Seidemann K, Jansen P, et al.: Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 2000, 35:20–27.

    Article  PubMed  CAS  Google Scholar 

  29. Link MP, Shuster JJ, Donaldson SS, et al.: Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med 1997, 337:1259–1266.

    Article  PubMed  CAS  Google Scholar 

  30. Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999, 94:3294–3306.

    PubMed  CAS  Google Scholar 

  31. Cairo MS, Sposto R, Hoover-Regan M, et al.: Childhood and adolescent large-cell lymphoma (LCL): a review of the Children’s Cancer Group experience. Am J Hematol 2003, 72:53–63.

    Article  PubMed  Google Scholar 

  32. Seidemann K, Tiemann M, Schrappe M, et al.: Shortpulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001, 97:3699–3706.

    Article  PubMed  CAS  Google Scholar 

  33. Brugieres L, Deley MC, Pacquement H, et al.: CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998, 92:3591–3598.

    PubMed  CAS  Google Scholar 

  34. Rosolen A, Pillon M, Garaventa A, et al.: Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer 2005, 104:2133–2140.

    Article  PubMed  CAS  Google Scholar 

  35. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds.): World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

    Google Scholar 

  36. Goldsby RE, Carroll WL: The molecular biology of pediatric lymphomas. J Pediatr Hematol Oncol 1998, 20:282–296.

    Article  PubMed  CAS  Google Scholar 

  37. Amati B, Land H: Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev 1994, 4:102–108.

    Article  PubMed  CAS  Google Scholar 

  38. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ: Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 2005, 41:2485–2501.

    Article  PubMed  CAS  Google Scholar 

  39. Cinti C, Claudio PP, Howard CM: Genetic alterations disrupting the nuclear localization of the retinoblastomarelated gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res 2000, 60:383–389.

    PubMed  CAS  Google Scholar 

  40. Bellan C, Lazzi S, De Falco G: Burkitt’s lymphoma: new insights into molecular pathogenesis. J Clin Pathol 2003, 56:188–192.

    Article  PubMed  CAS  Google Scholar 

  41. Legoux R, Delpech B, Dumont X, et al.: Cloning and expression in Escherichia coli of the gene encoding Aspergillus fiavus urate oxidase. J Biol Chem 1992, 267:8565–8570.

    PubMed  CAS  Google Scholar 

  42. Pui CH, Mahmoud HH, Wiley JM, et al.: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001, 19:697–704.

    PubMed  CAS  Google Scholar 

  43. Goldman SC, Holcenberg JS, Finklestein JZ, et al.: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97:2998–3003.

    Article  PubMed  CAS  Google Scholar 

  44. Jeha S, Kantarjian H, Irwin D, et al.: Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005, 19:34–38.

    PubMed  CAS  Google Scholar 

  45. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL: Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer 2005, 45:753–769. A thorough review of the individual molecular characteristics of the different types of non-Hodgkin’s lymphomas.

    Article  PubMed  Google Scholar 

  46. National Cancer Institute: Childhood Non-Hodgkin’s Lymphoma. Available at http://www.cancer.gov/cancertopics/ pdq/treatment/child-non-hodgkins/healthprofessional Accessed 7/12/06.

  47. Savage KJ, Monti S, Kutok JL, et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871–3879.

    Article  PubMed  CAS  Google Scholar 

  48. Lones MA, Perkins SL, Sposto R, et al.: Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an excellent outcome: a Children’s Cancer Group report. J Clin Oncol 2000, 18:3845–3853.

    PubMed  CAS  Google Scholar 

  49. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235–242.

    Article  PubMed  CAS  Google Scholar 

  50. de Vries MJ, Veerman AJ, Zwaan CM: Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin’s lymphoma. Br J Haematol 2004, 125:414–415.

    Article  PubMed  Google Scholar 

  51. Liang X, Meech SJ, Odom LF, et al.: Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol 2004, 121:496–506.

    Article  PubMed  Google Scholar 

  52. Ladanyi M: The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma. Cancer Surv 1997, 30:59–75.

    PubMed  CAS  Google Scholar 

  53. Ruchatz H, Coluccia AM, Stano P, et al.: Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp Hematol 2003, 31:309–315.

    Article  PubMed  CAS  Google Scholar 

  54. Bai RY, Ouyang T, Miething C, et al.: Nucleophosminanaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000, 96:4319–4327.

    PubMed  CAS  Google Scholar 

  55. Morris SW, Xue L, Ma Z, Kinney MC: Alk + CD30 + lymphomas: a distinct molecular genetic subtype of non-Hodgkin’s lymphoma. Br J Haematol 2001, 113:275–295.

    Article  PubMed  CAS  Google Scholar 

  56. Kumar S, Pittaluga S, Raffeld M, et al.: Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol 2005, 8:52–60.

    Article  PubMed  Google Scholar 

  57. Bayle C, Charpentier A, Duchayne E, et al.: Leukaemic presentation of small cell variant anaplastic large cell lymphoma: report of four cases. Br J Haematol 1999, 104:680–688.

    Article  PubMed  CAS  Google Scholar 

  58. Muto A, Nakagawa A, Shimomura Y, et al.: Antineoplastic agents for pediatric anaplastic large cell lymphoma: Vinblastine is the most effective in vitro. Leuk Lymphoma 2005, 46:1489–1496.

    Article  PubMed  CAS  Google Scholar 

  59. Brugieres L, Quartier P, Le Deley MC, et al.: Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology. Ann Oncol 2000, 11:53–58.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA

    Tanya M. Trippett MD

Authors
  1. Neerav N. Shukla MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanya M. Trippett MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tanya M. Trippett MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shukla, N.N., Trippett, T.M. Non-Hodgkin’s lymphoma in children and adolescents. Curr Oncol Rep 8, 387–394 (2006). https://doi.org/10.1007/s11912-006-0062-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0062-0

Keywords

Search

Navigation